 |
40 Diseases |  |
0 Trials |
|
0 Trials |  |
41 News |  |
- pradigastat (LCQ908) / Novartis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of ANJ908, a Novel DGAT1 Inhibitor, in Patients With Chronic Idiopathic Constipation (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_619;
Patients were 77.9% female, with a mean (SD) age and BMI of 42.2 (14.4) years and 23.2 (4.36) kg/m 2 , respectively. ANJ908 increased the mean (SE) placebo-subtracted number of SBM/week by +2.28 (0.75; p = 0.0027) and +3.10 (0.74; p < 0.0001) and CSBM/week by +1.53 (0.70; p = 0.03) and +1.81 (0.70; p = 0.01), respectively at week 4.
- ||| pradigastat (LCQ908) / Novartis
Trial completion, Trial primary completion date: A Proof of Concept Study of Pradigastat in Patients With Functional Constipation (clinicaltrials.gov) - Jun 8, 2022
P2, N=181, Completed, Sponsor: Anji Pharma
ANJ908 increased the mean (SE) placebo-subtracted number of SBM/week by +2.28 (0.75; p = 0.0027) and +3.10 (0.74; p < 0.0001) and CSBM/week by +1.53 (0.70; p = 0.03) and +1.81 (0.70; p = 0.01), respectively at week 4. Recruiting --> Completed | Trial primary completion date: Jan 2022 --> Apr 2022
- | pradigastat (LCQ908) / Novartis
Journal: DGAT1 inhibitors protect pancreatic β-cells from palmitic acid-induced apoptosis. (Pubmed Central) - Sep 2, 2021
We showed that DGAT1 inhibitors (4a and LCQ908) at the concentration of 1 μM significantly ameliorated palmitic acid (PA)-induced apoptosis in MIN6 pancreatic β-cells and primary cultured mouse islets; oral administration of a DGAT1 inhibitor (4a) (100 mg/kg) for 4 weeks significantly reduced the apoptosis of pancreatic islets in db/db mice...Furthermore, we revealed that pretreatment with 4a (1 μM) significantly alleviated PA-induced intracellular lipid accumulation, endoplasmic reticulum (ER) stress, and proinflammatory responses in MIN6 cells, which might contribute to the protective effects of DGAT1 inhibitors on pancreatic β-cells. These findings provided a better understanding of the antidiabetic effects of DGAT1 inhibitors.
- | pradigastat (LCQ908) / Novartis
Journal: A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism. (Pubmed Central) - Jun 22, 2021
Here we report a novel DGAT1 inhibitor, Yhhu2407, which showed a stronger DGAT1 inhibitory activity (IC = 18.24 ± 4.72 nM) than LCQ908 (IC = 78.24 ± 8.16 nM) in an enzymatic assay and led to a significant reduction in plasma TG after an acute lipid challenge in mice...In vivo study also disclosed that Yhhu2407 exerted a beneficial effect on regulating plasma TG and lipoprotein levels in rats, and effectively ameliorated high-fat diet (HFD)-induced dyslipidemia in hamsters. In conclusion, we identified Yhhu2407 as a novel DGAT1 inhibitor with potent efficacy on improving lipid metabolism in rats and HFD-fed hamsters without causing obvious adverse effects.
- || PK/PD data, Journal: Pharmacokinetics of current and emerging treatments for hypercholesterolemia. (Pubmed Central) - Jan 23, 2021
Newer oral agents including pemafibrate and bempedoic acid have generally favorable pharmacokinetics supporting use in a wide range of patients...The small-interfering RNA inclisiran has the notable advantage that a single subcutaneous administration may be effective for up to 6 months. The CV outcome trial results and long term safety data are eagerly awaited for these new agents.
- |||| pradigastat (LCQ908) / Novartis
New P2 trial: A Proof of Concept Study of Pradigastat in Patients With Functional Constipation (clinicaltrials.gov) - Nov 5, 2020
P2, N=180, Recruiting, Sponsor: Anji Pharma
- pradigastat (LCQ908) / Novartis
Trial initiation date: Efficacy of LCQ908 on Cardiovascular Risk (clinicaltrials.gov) - Apr 14, 2016
P2, N=41, Terminated, Sponsor: Novartis Pharmaceuticals
The CV outcome trial results and long term safety data are eagerly awaited for these new agents. Initiation date: Mar 2011 --> Dec 2011
- || pradigastat (LCQ908) / Novartis
Trial completion, Trial primary completion date: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. (clinicaltrials.gov) - Mar 18, 2016
P3, N=38, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2011 --> Dec 2011 Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2015
- pradigastat (LCQ908) / Novartis
Enrollment change, Trial termination: Efficacy of LCQ908 on Cardiovascular Risk (clinicaltrials.gov) - May 21, 2015
P2, N=41, Terminated, Sponsor: Novartis Pharmaceuticals
N=78 --> 41 | Recruiting --> Terminated; The study was terminated based on interim analysis. See detailed description.
- | pradigastat (LCQ908) / Novartis
Enrollment closed: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. (clinicaltrials.gov) - Jan 8, 2015
P3, N=38, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
See detailed description. Recruiting --> Active, not recruiting
- |||| pradigastat (LCQ908) / Novartis
Trial completion: Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients (clinicaltrials.gov) - Oct 15, 2014
P2, N=52, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || pradigastat (LCQ908) / Novartis
Trial completion: A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome (clinicaltrials.gov) - Jul 8, 2014
P3, N=45, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | pradigastat (LCQ908) / Novartis
Trial primary completion date: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. (clinicaltrials.gov) - Jun 26, 2014
P3, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Nov 2016
- || pradigastat (LCQ908) / Novartis
Trial primary completion date: Efficacy of LCQ908 on Cardiovascular Risk (clinicaltrials.gov) - May 29, 2014
P2, N=78, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2015 --> Nov 2016 Trial primary completion date: Jan 2014 --> Jun 2014
- | pradigastat (LCQ908) / Novartis
Enrollment closed: Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients (clinicaltrials.gov) - May 14, 2014
P2, N=45, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2014 --> Jun 2014 Recruiting --> Active, not recruiting
- || pradigastat (LCQ908) / Novartis
Trial primary completion date: Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients (clinicaltrials.gov) - May 4, 2014
P2, N=55, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2014 --> Sep 2014
- || pradigastat (LCQ908) / Novartis
Trial completion date: Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients (clinicaltrials.gov) - May 4, 2014
P2, N=55, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2014 --> Sep 2014 Trial completion date: Jul 2014 --> Sep 2014
- | pradigastat (LCQ908) / Novartis
Enrollment closed: A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome (clinicaltrials.gov) - Nov 20, 2013
P3, N=45, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2014 --> Sep 2014 Recruiting --> Active, not recruiting
- |||| pradigastat (LCQ908) / Novartis
Trial completion, Combination therapy: A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza (clinicaltrials.gov) - Aug 28, 2013
P2, N=58, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| pradigastat (LCQ908) / Novartis
Enrollment open: Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients (clinicaltrials.gov) - Jun 20, 2013
P2, N=55, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| pradigastat (LCQ908) / Novartis
Enrollment change: Efficacy of LCQ908 on Cardiovascular Risk (clinicaltrials.gov) - May 22, 2013
P2, N=78, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=52 --> 78
- ||| pradigastat (LCQ908) / Novartis
Trial completion: Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment (clinicaltrials.gov) - May 22, 2013
P1, N=53, Completed, Sponsor: Novartis Pharmaceuticals
N=52 --> 78 Recruiting --> Completed
- ||| pradigastat (LCQ908) / Novartis
Trial completion: Pharmacokinetics of LCQ908 in Patients With Renal Impairment (clinicaltrials.gov) - May 20, 2013
P1, N=58, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- ||||| pradigastat (LCQ908) / Novartis
New P2 trial: Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients (clinicaltrials.gov) - Mar 12, 2013
P2, N=55, Recruiting, Sponsor: Novartis Pharmaceuticals
- | pradigastat (LCQ908) / Novartis
Enrollment open: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. (clinicaltrials.gov) - Feb 10, 2013
P3, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| pradigastat (LCQ908) / Novartis
New P2 trial, Combination therapy: A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza (clinicaltrials.gov) - May 7, 2012
P2, N=58, Completed, Sponsor: Novartis Pharmaceuticals
- ||| pradigastat (LCQ908) / Novartis
New P1 trial: Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment (clinicaltrials.gov) - May 7, 2012
P1, N=53, Completed, Sponsor: Novartis Pharmaceuticals
- pradigastat (LCQ908) / Novartis
Trial termination, Monotherapy: A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients (clinicaltrials.gov) - May 5, 2012
P2, N=32, Terminated, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Terminated; Terminated early due to futility
- pradigastat (LCQ908) / Novartis
Enrollment change, Monotherapy: A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients (clinicaltrials.gov) - May 5, 2012
P2, N=32, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; Terminated early due to futility N=57 --> 32
- pradigastat (LCQ908) / Novartis
Enrollment change: Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia (clinicaltrials.gov) - May 2, 2012
P1/2, N=8, Completed, Sponsor: Novartis Pharmaceuticals
N=57 --> 32 N=36 --> 8
- pradigastat (LCQ908) / Novartis
Trial completion: Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia (clinicaltrials.gov) - May 2, 2012
P1/2, N=8, Completed, Sponsor: Novartis Pharmaceuticals
N=36 --> 8 Recruiting --> Completed
- ||| pradigastat (LCQ908) / Novartis
New P3 trial: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. (clinicaltrials.gov) - Apr 29, 2012
P3, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| pradigastat (LCQ908) / Novartis
New P1 trial: Pharmacokinetics of LCQ908 in Patients With Renal Impairment (clinicaltrials.gov) - Mar 18, 2012
P1, N=58, Completed, Sponsor: Novartis Pharmaceuticals
- ||| pradigastat (LCQ908) / Novartis
New P3 trial: A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome (clinicaltrials.gov) - Jan 19, 2012
P3, N=45, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- |||| pradigastat (LCQ908) / Novartis
Enrollment open: Efficacy of LCQ908 on Cardiovascular Risk (clinicaltrials.gov) - Jan 10, 2012
P2, N=78, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| pradigastat (LCQ908) / Novartis
New P2 trial: Efficacy of LCQ908 on Cardiovascular Risk (clinicaltrials.gov) - Nov 16, 2011
P2, N=78, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||| pradigastat (LCQ908) / Novartis
Trial completion: A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Oct 2, 2011
P2, N=693, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed